EAM
MRTX

EverPoint Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

EverPoint Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-125,000
Closed -$4.3M – 549
2015
Q3 		$4.3M Buy
+125,000
New +$3.78M 0.11% 237

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EverPoint Asset Management's MRTX Position: Q4 2015 in Review

EverPoint Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2015, closing a stake of 125,000 shares — an estimated $4.3M sold.

EverPoint Asset Management first reported a position in MRTX in Q3 2015 and held it in 1 quarter. The position peaked at $4.3M in Q3 2015. 80 funds tracked by Wall St. Rank hold MRTX as of Q4 2015.

  • EverPoint Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 125,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $4.3M.
  • EverPoint Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • EverPoint Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $4.3M in Q3 2015.
  • 80 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2015.

Based on EverPoint Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.